Physician profile
Steven Dunder
NPI 1346264546
$19,751.14
in general payments reported to CMS, 2019-2025
89 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,040 · 2020: $2,973 · 2021: $1,873 · 2022: $4,175 · 2023: $2,301 · 2024: $2,326 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,242 · Education: $299 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,241.66 |
| Education | $298.77 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,971.71 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $1,818.38 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| G1 Therapeutics, INC. | $1,514.21 | 2022 | |
| Janssen Biotech, INC. | $1,103.61 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $943.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $898.56 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $742.29 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $719.08 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Celgene Corporation | $617.39 | 2020-2025 | Reblozyl, Pomalyst, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $549.01 | 2019-2023 | Epkinly, Imbruvica |
| Abbvie INC. | $548.53 | 2019-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $541.60 | 2019-2025 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $499.55 | 2021-2025 | Enhertu, Vanflyta |
| Seagen INC. | $499.04 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Asd Specialty Healthcare, LLC | $426.74 | 2019-2025 |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $363.22 | 2020-2025 | |
| Astellas Pharma US INC | $360.72 | 2019-2025 | Vyloy, Xospata |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $298.72 | 2022-2024 | Ultomiris |
| Amgen INC. | $284.94 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Octapharma USA, INC. | $284.82 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Incyte Corporation | $259.34 | 2020-2023 | Monjuvi, Pemazyre, Jakafi |
| Foundation Medicine, INC. | $219.74 | 2019-2023 | Foundationone Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $182.14 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Tersera Therapeutics LLC | $181.79 | 2022-2025 | Zoladex, Xermelo |
| Regeneron Healthcare Solutions, INC. | $159.97 | 2022-2025 | Libtayo, Lynozyfic |
| Organon LLC | $155.88 | 2022-2023 | Ontruzant |
| Jazz Pharmaceuticals INC. | $152.53 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Talvey |
| Emd Serono, INC. | $148.44 | 2019-2023 | Bavencio |
| Array Biopharma INC | $137.97 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Genzyme Corporation | $133.63 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $132.06 | 2022-2025 | Onivyde, Tazverik |
| Lilly USA, LLC | $128.90 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $127.12 | 2020-2025 | Ayvakit |
| Gilead Sciences, INC. | $118.61 | 2021-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $101.36 | 2022-2025 | |
| Exelixis INC. | $100.35 | 2019-2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $94.72 | 2022-2025 | Clonoseq |
| Histosonics, INC. | $93.12 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.35 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $82.33 | 2019-2023 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $81.29 | 2023-2025 | Fotivda |
| Stemline Therapeutics INC. | $80.59 | 2024-2025 | Orserdu, Elzonris |
| Karyopharm Therapeutics INC. | $78.67 | 2020-2023 | Xpovio |
| Taiho Oncology, INC. | $72.21 | 2020-2025 | |
| Dova Pharmaceuticals | $70.51 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.02 | 2022-2025 | |
| Pharmaessentia USA Corporation | $66.63 | 2022-2023 | Besremi |
| Beone Medicines USA, INC. | $66.27 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $62.49 | 2023 | Vonjo |
| Epizyme, INC. | $60.49 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $59.27 | 2019-2023 | Tavalisse, Rezlidhia |
| Myovant Sciences INC. | $42.49 | 2021-2022 | |
| Morphosys, US INC. | $42.09 | 2021 | |
| Kite Pharma, INC. | $37.36 | 2020-2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $34.06 | 2025 | Monoferric |
| Blue Earth Diagnostics | $33.61 | 2019 | |
| Kyowa Kirin, INC. | $31.21 | 2019-2020 | |
| Mylan Institutional INC. | $31.16 | 2020-2021 | |
| Sobi, INC | $27.47 | 2022-2024 | |
| Myriad Genetic Laboratories, INC. | $25.44 | 2022-2023 | Precisetumor |
| Novocure INC. | $24.58 | 2019-2022 | |
| Heron Therapeutics, INC. | $23.46 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $22.15 | 2022 | |
| Verity Pharmaceuticals INC. | $20.83 | 2023 | Trelstar |
| Catalyst Pharmaceuticals, INC. | $20.04 | 2023 | Firdapse |
| Clovis Oncology, INC. | $19.37 | 2022 | |
| Eusa Pharma (US) LLC | $18.76 | 2022 | |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Orgovyx |
| Iovance Biotherapeutics, INC. | $18.45 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $17.94 | 2021 | |
| Syndax Pharmaceuticals, INC. | $17.85 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.47 | 2022 | |
| Boston Scientific Corporation | $15.24 | 2025 | Spaceoar Vue System - 10ml |
| Fresenius Kabi USA, LLC | $15.22 | 2025 | |
| Aurobindo Pharma USA, INC. | $14.57 | 2019 | |
| Spectrum Pharmaceuticals INC. | $14.09 | 2025 | Rolvedon |
| Tolmar Pharmaceuticals, INC. | $13.98 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.85 | 2024 | Givlaari |
| Beigene USA, INC. | $13.34 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $12.66 | 2019 | |
| Puma Biotechnology, INC. | $12.04 | 2022 | |
| Coherus Oncology, INC. | $11.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $10.92 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $489Tukysa $410Reblozyl $377Ibrance $371Enhertu $345Talvey $337Epkinly $329Lenvima $276Imfinzi $265Imbruvica $262Darzalex $245Octagam Immune Globulin (Human) $240Tecvayli $220Erleada $158Pomalyst $147Adcetris $143Tagrisso $139Mektovi $138Braftovi $138Opdivo $124Padcev $119Venclexta $118Calquence $115Xtandi $115Opdualag $93.84Carvykti $90.74Elrexfio $88.70Xalkori $87.89Lorbrena $87.89Pluvicto $87.29Onivyde $86.57Fotivda $81.29Zoladex $77.43Vonjo $76.90Paxlovid $75.15Welireg $75.00Libtayo $73.95Lutathera $72.96Tivdak $72.29Lynparza $72.22Orgovyx $72.03Rybrevant $70.69Scemblix $70.17Xermelo $70.05Tecentriq $67.73Brukinsa $66.27Kisqali $64.12Orserdu $63.52Fabhalta $60.71Jaypirca $59.85Verzenio $59.85Tibsovo $59.19Lynozyfic $58.59Clonoseq $54.65Bosulif $52.98Nubeqa $52.51Monjuvi $51.72Pemazyre $51.72Zepzelca $51.24Piqray $50.63Alecensa $49.21Comirnaty $48.90Talzenna $48.14Ultomiris $43.83Vyloy $39.66Inlyta $37.89Stivarga $37.79Vitrakvi $37.79Lumakras $37.74Eliquis $37.01Jakafi $35.95Pyrukynd $35.84Tasigna $34.76Iclusig $34.39Monoferric $34.06Trodelvy $33.59Retevmo $31.20Akeega $29.96Xospata $28.91Bavencio $28.76Zejula $28.36Jemperli $28.36Cabometyx $28.12Panzyga $26.01Ayvakit $25.87Yescarta $25.83Voranigo $22.46Inqovi $21.25Lonsurf $21.25Trelstar $20.83Foundationone Cdx $20.65Fruzaqla $20.55Besremi $20.29Firdapse $20.04Tazverik $19.23Ontruzant $18.97Vanflyta $18.83Ninlaro $18.54Amtagvi $18.45Tavalisse $18.00
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dunder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.